BioVaxys Technology (BioVaxys Technology) Change In Payables And Accrued Expense : $1.45 Mil (TTM As of Jul. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Change In Payables And Accrued Expense?

BioVaxys Technology's Change In Payables And Accrued Expense for the quarter that ended in Jul. 2023 was $0.22 Mil. It means BioVaxys Technology's Accounts Payable & Accrued Expense increased by $0.22 Mil from Apr. 2023 to Jul. 2023 .

BioVaxys Technology's Change In Payables And Accrued Expense for the fiscal year that ended in Oct. 2022 was $1.56 Mil. It means BioVaxys Technology's Accounts Payable & Accrued Expense increased by $1.56 Mil from Oct. 2021 to Oct. 2022 .

BioVaxys Technology Change In Payables And Accrued Expense Historical Data

The historical data trend for BioVaxys Technology's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Change In Payables And Accrued Expense Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Change In Payables And Accrued Expense

-0.01

0.12

-0.42

1.56

BioVaxys Technology Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															0.53	0.56	0.76	-0.09	0.22

BioVaxys Technology Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jul. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.45 Mil.

BioVaxys Technology Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology (BioVaxys Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.